Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention
- 610 Downloads
We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999–2004) was examined. Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and zoster ophthalmicus). The risk for OI was significantly higher in the first year of treatment (odds ratio [OR] 8; 95% confidence interval [CI] 2–50). Previous treatment with more than two immunosuppressive drugs was the only factor related to OI (OR 8.686; 95% CI 1.889–39.943). We identified the subset of patients treated with infliximab who had a higher risk for OI. The screening of latent infections is key to diminishing the incidence of these infections.
KeywordsInfliximab Opportunistic Infection Connective Tissue Disease Visceral Leishmaniasis Invasive Aspergillosis
Part of these results have been presented previously at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 27–30 September 2006, San Francisco, CA. We thank David García-Cortés for his value technical assistance.
- 8.Elkayam O, Caspi D, Reitblatt T et al (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33:283–288. doi: 10.1053/j.semarthrit.2003.10.003 PubMedCrossRefGoogle Scholar
- 23.Dixon WG, Watson K, Lunt M et al (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376. doi: 10.1002/art.21978 PubMedCrossRefGoogle Scholar